A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes
复制标题
DOI：
10.1007/s13340-022-00605-x
复制
发表时间：
2022-12-23
影响因子：
2.2
通讯作者：
Yamauchi, Toshimasa
中科院分区：
文献类型：
--
作者：
Bouchi, Ryotaro;Kondo, Tatsuya;Yamauchi, Toshimasa
2020年，日本糖尿病学会（JDS）通过了一项全面的决定，就需要不时更新的糖尿病管理相关问题发布共识声明，并成立了“JDS共识声明制定委员会”。这些共识声明旨在根据目前针对每个问题的可用证据，介绍委员会对日本糖尿病管理的看法。因此，我们希望执业糖尿病学家将永远不会不咨询这些声明，以提供最佳的做法，在各自的临床设置。值得注意的是，虽然世界上多达三分之一的糖尿病患者集中在亚洲地区，但糖尿病的病理学，包括受影响患者的肥胖程度，在东西方之间存在差异。此外，鉴于日本及时发表的共识性声明对临床实践的影响巨大，因此，在2020年发表了第一份共识性声明《糖尿病患者的医学营养治疗和饮食咨询》之后，还计划将每一份共识性声明都提供英文版本。（Tonyobyou。二○二○年;第六十三条第三款：91-109），该委员会借此机会在本声明中提出了一个共识“糖尿病患者药物治疗算法”。有三个原因促使委员会解决这个问题。首先，西方人和日本人之间的糖尿病病理学存在特征性差异，
In 2020, the Japan Diabetes Society (JDS) adopted a sweeping decision to release consensus statements on relevant issues in diabetes management that require updating from time to time and launched a “JDS Committee on Consensus Statement Development”. These consensus statements are intended to present the committee's take on diabetes management in Japan based on evidence currently available for each of the issues addressed. It is thus hoped that practicing diabetologists will never fail to consult these statements to provide the best available practice in their respective clinical settings. Of note, while as many as one-third of all people with diabetes in the world are shown to be concentrated in the Asian region, diabetes mellitus varies in its pathology, including the extent of obesity involved in affected patients, between the East and West. Again, given that timely consensus statements to come out of Japan are thus expected to have enormous implications for clinical practice, it is also planned to make each consensus statement available in English.Following publication in 2020 of the committee’s first consensus statement on “Medical Nutrition Therapy and Dietary Counseling for People with Diabetes.”(Tonyobyou. 2020; 63 (3): 91–109) in Japanese, the committee has taken this opportunity to propose a consensus “algorithm for pharmacotherapy in people with diabetes”, in this statement. There are three reasons that prompted the committee to address this issue. First, there are characteristic differences in diabetes pathology between Westerners and the Japanese,